Breaking Free from Commercial Limitations with Custom Chemical Synthesis
In the vast landscape of pharmaceutical research and development, one significant challenge that researchers face is the availability of suitable
Read more
Drug Development
Coya Therapeutics’ COYA 301 (interleukin-2) Shows Promising Results in Open Label Alzheimer’s Study
Coya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read more
Eisai Partners with BlissBio to Jointly Develop ADC for Multiple Cancer Types
Eisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read more
EScalate Assay Enables Robust and Accurate Determination of Plasma Protein Binding
Determination of the Plasma Protein Binding of Liraglutide Using the EScalate* Equilibrium Shift Assay A Sovicell White Paper Evaluation of
Read more
Ori Biotech Raises €88M to Automate Cell Therapy Manufacture
Ori Biotech, based in the United Kingdom, has secured €88 million ($100 million) in its Series B funding to help
Read more
Sanofi and Exscientia Partner to Develop AI-driven Pipeline of Precision-Engineered Medicines
French pharma giant Sanofi and British pharmatech business Exscientia revealed a ground-breaking research cooperation and licensing agreement to develop up
Read more
Evotec Wins € 7.5 Mill Grant for Development of First-in-class COVID-19 Therapeutic
Evotec, a publicly listed drug discovery and development company, has won a € 7.5 million grant for the development of
Read more
Genentech’s Investigational Antibody Wins BTD for Alzheimer’s Treatment
Genentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read more
Tezepelumab gets ODD in the US for Eosinophilic Esophagitis
Tezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read more
Takeda and JCR to Commercialize Next-Gen Hunter Syndrome Therapy
Takeda and JCR Pharmaceuticals announced today a geo-based exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an
Read more